A phase IA, dose-escalating study of LBH589 administered intravenously in adult patients with advanced solid tumors

被引：0
|
作者：
Oizumi, S. [1 ]
Ando, Y. [2 ]
Kitagawa, K. [2 ]
Morita, S. [2 ]
Komatsu, Y. [3 ]
Yuki, S. [3 ]
Fujiwara, Y. [4 ,5 ]
Kiyota, N. [4 ,5 ]
Kobayashi, K. [6 ]
Minami, H. [4 ,5 ]
机构：
[1] Hokkaido Univ, Sch Med, Dept Med 1, Sapporo, Hokkaido 060, Japan
[2] Nagoya Univ Hosp, Dept Clin Oncol & Chemotherapy, Nagoya, Aichi, Japan
[3] Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hematol, Sapporo, Hokkaido, Japan
[4] Kobe Univ Hosp, Kobe, Hyogo, Japan
[5] Grad Sch Med, Dept Med, Kobe, Hyogo, Japan
[6] Novartis Pharma KK, Oncol Translat Med, Tokyo, Japan
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72099-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：124 / 125
页数：2
相关论文
共 50 条
  • [31] Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan-Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.
    Ottmann, Oliver G.
    Spencer, Andrew
    Prince, H. Miles
    Bhalla, Kapil N.
    Fischer, Thomas
    Liu, Angela
    Parker, Kathryn
    Jalaluddin, Muhammad
    Laird, Glen
    Woo, Margaret
    Scott, Jeffrey W.
    DeAngelo, Daniel J.
    BLOOD, 2008, 112 (11) : 352 - 353
  • [32] A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in low-grade neuroendocrine tumors
    Rajguru, Saurabh
    Lubner, Sam Joseph
    Mulkerin, Daniel
    Schelman, William R.
    Winterle, Natalie
    Holen, Kyle D.
    Leverson, Glen
    Chen, Herbert
    LoConte, Noelle K.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies
    Munster, P. N.
    Petrou, P.
    Ryan, C. J.
    Jahan, T. M.
    DuBois, S. G.
    Rugo, H. S.
    Chan, J. K.
    Thurn, K. T.
    Reinert, A.
    Daud, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies
    Moore, A. P.
    Thomas, S.
    Ryan, C. J.
    Jahan, T. M.
    DuBois, S. G.
    Chan, J. K.
    Thurn, K. T.
    Reinhert, A.
    Daud, A.
    Munster, P. N.
    EJC SUPPLEMENTS, 2010, 8 (07): : 130 - 131
  • [35] A pharmacokinetic and dose-escalating study of paclitaxel injection concentrate for nano-dispersion (PICN) alone and with carboplatin in patients with advanced solid tumors
    Ma, Wen Wee
    Lam, Elaine Tat
    Dy, Grace K.
    Diamond, Jennifer Robinson
    Zhao, Yujie
    Bui, Lynne A.
    Fetterly, Gerald J.
    Abramowitz, Wattanaporn
    Harning, Ronald
    Pencheva, Pepi
    Bhowmik, Shravanti
    Divekar, Ganesh Harishchandra
    DiRaddo, Ann Marie
    Eckhardt, S. Gail
    Adjei, Alex A.
    Jimeno, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors
    Rosenthal, E. L.
    Chung, T. K.
    Parker, W. B.
    Allan, P. W.
    Clemons, L.
    Lowman, D.
    Hong, J.
    Hunt, F. R.
    Richman, J.
    Conry, R. M.
    Mannion, K.
    Carroll, W. R.
    Nabell, L.
    Sorscher, E. J.
    ANNALS OF ONCOLOGY, 2015, 26 (07) : 1481 - 1487
  • [37] Phase I dose-escalating PoC study to evaluate the safety and tolerability of LiPlaCis (liposomal cisplatin formulation) in patients with advanced or refractory tumors
    Lassen, Ulrik
    Mau-Sorensen, Morten
    Buhl, Ulla Hald
    Madsen, Mogens W.
    Balslev, Eva
    Pluim, Dick
    Schellens, Jan H. M.
    Knudsen, Steen
    Jensen, Peter B.
    CANCER RESEARCH, 2016, 76
  • [38] A dose-escalating phase I study with valproic acid (VPA) in patients (pts) with advanced cancer.
    Atmaca, A
    Maurer, A
    Heinzel, T
    Göttlicher, M
    Neumann, A
    Al-Batran, SE
    Martin, E
    Bartsch, I
    Knuth, A
    Jaeger, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 236S - 236S
  • [39] A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies.
    Moore, A. P.
    Thomas, S.
    Ryan, C. J.
    Jahan, T. M.
    DuBois, S. G.
    Chan, J. K.
    Thurn, K. T.
    Collisson, E. A.
    Reinert, A.
    Daud, A.
    Munster, P. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Phase I, dose-escalating study of elisidepsin (Irvalec®), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors
    Goel, Sanjay
    Viteri, Santiago
    Moran, Teresa
    Coronado, Cinthya
    Iglesias Dios, Jorge Luis
    Miguel-Lillo, Bernardo
    Fernandez-Garcia, Eva M.
    Rosell, Rafael
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (01) : 75 - 83
12345